Candidate Molecules and ki-67/MIB1 as Novel Diagnostic Biomarker for Human Uterine Mesenchymal Tumors

Takuma Hayashi, Akiko Horiuchi, Nobuo Yaegashi, Susumu Tonegawa, Ikuo Konishi

Department of Immunology and Infectious Disease, Shinshu University School of Medicine,Matsumoto, Nagano, Japan; Department of Obstetrics and Gynecology, Kyoto University Graduate School of Medicine,Kyoto-city, Kyoto, Japan.
Department of Obstetrics and Gynecology, Kyoto University Graduate School of Medicine, Kyoto-city, Kyoto, Japan.
Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Miyagi Japan.
Horiuchi Ladies Clinic, Matsumoto, Nagano 390-0821, Japan.
Picower Institution and Department of Biology, Massachusetts Institute of Technology,Cambridge, MA 02139-4307 USA.

DOI: 10.4236/ijmpcero.2013.23B001                

Abstract

Human uterine leiomyosarcoma (LMS) develops more often in the muscle tissue layer of the uterine body than in the uterine cervix. The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known. Importantly, a diagnostic-biomarker, which distinguishes malignant uterine LMS from benign tumor leiomyoma (LMA), is yet to be established. Accordingly, it is necessary to analyze risk factors associated with uterine LMS, to establish a clinical treatment method. Protea some β-ring subunit LMP2/β1i-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ~40% by 14 months of age. We found LMP2/β1i expression to be absent in human uterine LMS, but present in human LMA. Therefore, defective-LMP2/β1i expression may be one of the risk factors for human uterine LMS. LMP2/β1i is a potential diagnostic-biomarker under the combination of candidate molecules, for instance cyclin B1, cyclin E and calponin h1 and ki-67/MIB1 counts for uterine mesenchymal tumors, especially human uterine LMS, and may be a targeted-molecule for a new therapeutic approach.

Keywords

LMP2/β1i; Uterine Leiomyosarcoma; Uterine Leiomyoma; Biomarker

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	C. Zaloudek and M. R. Hendrickson, “Mesenchymal tumors of the uterus, in R. J. Kurman (ed): Blaustein’s Pathology of the Female Genital Tract (ed 5),” New York, Springer-Verlag, Vol. 5, 2002, pp. 561-578.
[2]	T. I. Wu, T. C. Chang, S. Hsueh, K. H. Hsu, H. H. Chou, H. J. Huang and C. H. Lai, “Prognostic Factors and Impact of Adjuvant Chemotherapy for Uterine Leiomyosarcoma,” Gynecologic Oncology, Vol. 100, No. 1, 2006, pp.166-172. doi: /10.1016/j.ygyno.2005.08.010
[3]	M. M. Leitao, R. A. Soslow, D. Nonaka, A. B. Olshen, C. Aghajanian, P. Sabbatini, J. Dupont, M. Hensley, Y. Sonoda, R. R. Barakat and S. Anderson, “Tissue Microarray Immunohisto Chemical Expression of Estrogen, Progesterone, and Androgen Receptors in Uterine Leiomyomata and Leiomyosarcoma,” Cancer ,Vol. 101, No. 6, 2004, pp. 1455-1462. doi:10.1002/cncr.20521
[4]	E. A. Perez, L. Pusztai and M. Van de Vijver, “Improving Patient Care through Molecular Diagnostics,” Seminars in Oncology, Vol. 31, No. 10, 2004, pp. 14-20. doi:10.1053/j.seminoncol.2004.07.017
[5]	http://www.cancer.gov/cancertopics/pdq/treatment/uterine sarcoma/HealthProfessional/page1#Section_87
[6]	http://cancer.gov/cancertopics/pdq/treatment/uterine sarcoma/HealthProfessional
[7]	H. L. Evans, S. P. Chawla, C. Simpson and K. P. Finn, “Smooth Muscle Neoplasms of the Uterus Other than Ordinary Leiomyoma,” A Study of 46 Cases, with Emphasis on Diagnostic Criteria and Prognostic Factors, Cancer, Vol. 62, No. 10, 1988, pp. 2239-2247. doi:10.1002/1097-0142(19881115)62:10<2239::AID-CNCR2820621028>3.0.CO;2-Y
[8]	R. J. Kurma, “Pathology of the Female Genital Tract,” 4th edition, Springer-Verlag; New York, Vol. 4, 2001, p. 499.
[9]	Diagnostic Criteria for LMS, Adapted from 2003 WHO Guidelines: World Health Organization Classification of Tumours: Pathology and Genetics, Pathology and Genetics of Tumours of the Breast and Female Genital Organs, IARC Press, France, 2003.
[10]	J. F. Lin and B. M. Slomovitz, “Uterine Sarcoma,” Current Oncology Reports, Vol. 10, No. 6, 2008, pp. 512-518. doi:10.1007/s11912-008-0077-9
[11]	F. Amant, A. Coosemans, M. Debiec-Rychter, D. Timmerman and I. Vergote, “Clinical Management of Uterine Sarcomas,” The Lancet Oncology, Vol. 10, No. 12, 2009, pp. 1188-1198. doi:10.1016/S1470-2045(09)70226-8
[12]	M. Miettinen and J. F. Fetsch, “Evaluation of Biological Potential of Smooth Muscle Tumours,” Histopathology, Vol. 48, No. 1, 2006, pp. 97-105. doi:10.1111/j.1365-2559.2005.02292.x
[13]	J. M. Peters, W. W. Franke and J. A. Kleinschmidt, Distinct 19 S and 20 S Subcomplexes of the 26 S Proteasome and Their Distribution in the Nucleus and the Cytoplasm,” Journal of Biological Chemistry, Vol. 269, 1994, pp.7709-7718.
[14]	H. Lodish, A. Berk, P. Matsudaira, C. A. Kaiser, M. Krieger, M. P. Scott, S. L. Zipursky and J. Darnell, 2004 "3", Mol Cell Biol (5th ed.), New York: W. H. Freeman and CO. Vol. 5, 2004, pp. 66-72.
[15]	I. M. Konstantinova, A. S. Tsimokha and A. G. Mittenberg, “Role of Proteasomes in Cellular Regulation,” International Review Cell and Molecular Biology, Vol. 267, 2008, pp. 59-124. doi:10.1016/S1937-6448(08)00602-3
[16]	J. Wang and M. A. Maldonado, “TheUbiquitin-Proteasome System and Its Role in Inflammatory and Autoimmune Diseases,” Cell and Molecular Immunology, Vol. 3, 2006, pp. 255–261.
[17]	T. Muchamuel, M. Basler, M. A. Aujay, E. Suzuki, K. W. Kalim, C. Lauer, C. Sylvain, E. R. Ring, J. Shields, J. Jiang, P. Shwonek, F. Parlati, S. D. Demo, M. K. Bennett, C. J. Kirk and M. Groettrup, “A Selective Inhibitor of the Immunoproteasome Subunit LMP7 Blocks Cytokine Production and Attenuates Progression of Experimental Arthritis,” Nature Medicine, Vol. 15, 2009, pp.781-788. doi:10.1038/nm.1978
[18]	L. Van Kaer, P. G. Ashton-Rickardt, M. Eichelberger, M. Gaczynska, K. Nagashima, K. L. Rock, A. L. Goldberg, P. C. Doherty and S. Tonegawa, “Altered Peptidase and Viral-specific T Cell Response in LMP2 Mutant Mice,” Immunity, Vol. 1, 1994, pp. 533-541.
[19]	T. Hayashi and D. L. Faustman, “Development of Spontaneous Uterine Tumors in Low Molecular Mass Polypeptide-2 Knockout Mice,” Cancer Research, Vol. 62, 2002, pp. 24-27. http://cancerres.aacrjournals.org/content/62/1/24
[20]	T. Hayashi, A. Horiuchi, K. Sano, N. Hiraoka, Y. Kanai, T. Shiozawa, S. Tonegawa and I. Konishi, “Molecular Approach on Uterine Leiomyosarcoma: LMP2-deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma,” Sarcoma 2011: 476498, Epub 2011 Mar 8, http://www.hindawi.com/journals/srcm/2011/476498/
[21]	T. Hayashi, Y. Kobayashi, S. Kohsaka and K. Sano, “Mutation in the ATP-binding Region of JAK1, Identified in Human Uterine Leiomyosarcomas, Results in Defective Interferon-gamma Inducibility of TAP1 and LMP2,” Oncogene, Vol. 25, 2006, pp. 4016-4026. doi:10.1038/sj.onc.1209434
[22]	T. Hayashi, A. Horiuchi, K. Sano, N. Hiraoka, M. Kasai, T. Ichimura, S. Nagase, O. Ishiko, Y. Kanai, N. Yaegashi, H. Aburatani, T. Shiozawa, S. Tonegawa and I. Konishi, “Potential Role of LMP2 as Tumor-suppressor Defines New Targets for Uterine Leiomyosarcoma Therapy,” Scientific Reports, Vol. 1, 2011, p. 180. doi:10.1038/srep00180
[23]	Y. L. Zhai, Y. Kobayashi, A. Mori, A. Orii, T. Nikaido, I. Konishi and S. Fujii, “Expression of Steroid Receptors, Ki-67, and p53 in Uterine Leiomyosarcomas,” International Journal Gynecological Pathology, Vol. 18, No. 1,2004, pp. 20-28. doi:10.1097/00004347-199901000-00004
[24]	T. Hayashi, A. Horiuchi, K. Sano, N. Hiraoka, M. Kasai, T. Ichimura, S. Nagase, O. Ishiko, Y. Kanai, N. Yaegashi, H. Aburatani, T. Shiozawa, S. Tonegawa and I. Konishi, “Potential role of LMP2 as an Anti-oncogenic Factor in Human Uterine Leiomyosarcoma: Morphological Significance of Calponin h1,” FEBS Letter, Vol. 586, 2012, pp. 1824-1831. doi:10.1016/j.febslet.2012.05.029
[25]	T. Hayashi, A. Horiuchi, K. Sano, N. Hiraoka, T. Ichimura, T. Sudo, O. Ishiko, N. Yaegashi, H. Aburatani and I. Konishi, “Potential Diagnostic Biomarkers for Human Uterine Mesenchymal Tumors: Especially LMP2/β1i and Cyclin B1-differential Expression,” Oncology Letters, 2013.
[26]	H. X. Wang, H. M. Wang, Q. L. Li and P. L. Judoson, “Expression of Proteasome Subunits Low Molecular Mass Polypeptide (LMP) 2 and LMP7 in the Endometrium and Placenta of Rhesus Monkey (Macaca mulatta) during early Pregnancy,” Biology of Reproduction, Vol. 71, No. 4, 2004, pp. 1317-1324. doi:10.1095/biolreprod.104.030213
[27]	H. X. Wang, H. M. Wang, H. Y. Lin, Q. Yang, H. Zhang, B. K.Tsang and C. Zhu, “Proteasome Subunit LMP2 is Required for Matrix Metalloproteinase-2 and -9 expression and Activities in Human Invasive Extravillous Trophoblast Cell Line,” Journal of Cellular Physiology, Vol. 206, No. 3, pp. 616-623. doi:10.1002/jcp.20508
[28]	J. J. Fu, P. Lin, X. Y. Lv, X. J. Yan, H. X. Wang, C. Zhu, B. K. Tsang, X. G. Yu and H. Wang, “Low Molecular Mass Polypeptide-2 in Human Trophoblast: Over-expression in Hydatidiform Moles and Possible Role in Trophoblast Cell Invasion,” Placenta, Vol. 30, No. 4, 2009, pp. 305-312. doi:10.1016/j.placenta.2009.01.005
[29]	T. Hayashi, A. Horiuchi, H. Aburatani, N. Yaegashi, S. Tonegawa and I. Konishi, “A Potential Diagnostic Biomarker: Proteasome LMP2/β1i-differential Expression in Human Uterus Neoplasm,” Nature Proceedings 2012, March 2: hdl:10101/npre.2012.7082.1.
[30]	A. Horiuchi, T. Nikaido, K. Ito, Y. Zhai, A. Orii, S. Taniguchi, T. Toki and S. Fujii, “Reduced Expression of Calponin h1 in Leiomyosarcoma of the Uterus,” Lab Investment, Vol. 78, 1998, pp. 839-846. http://www.ncbi.nlm.nih.gov/pubmed/9690561
[31]	A. Horiuchi, T. Nikaido, S. Taniguchi and S. Fujii, “Possible Role of Calponin h1 as a Tumor Suppressor in Human Uterine Leiomyosarcoma,” Journal of the National Cancer Institute, Vol. 91, No. 9, 1999, pp.790-796. doi:10.1093/jnci/91.9.790
[32]	Y. L. Zhai, T. Nikaido, T. Shiozawa, A. Orii and S. Fujii, “Expression of Cyclins and Cyclin-dependent Kinases in Smooth Muscle Tumors of the Uterus,” International Journal of Cancer, Vol. 84, 1999, pp. 224-250.
[33]	P. P. Ip, A. N. Cheung and P. B. Clement, “Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP): A Clinicopathologic Analysis of 16 Cases,” The American Journal of Surgical Pathology, Vol. 33, 2009, pp. 992-1005. doi:10.1097/PAS.0b013e3181a02d1c
[34]	P. P. Ip, K. Y. Tse and K. F. Tam, “Uterine Smooth Muscle Tumors Other than the Ordinary Leiomyomas and LeioMyosarcomas: A Review of Selected Variants with Emphasis on Recent Advances and Unusual Morphology that may Cause Concern for Malignancy,” Advances in Anatomic Pathology, Vol. 17, 2010, pp. 91-112. doi:10.1097/PAP.0b013e3181cfb901
[35]	I. Vajtai, R. Sahli, A. Kappeler, E. R. Christ and R. W. Seiler, “Leiomyomatoid Angiomatous Neuroendocrine Tumor (LANT) of the Pituitary: A Distinctive Biphasic Neoplasm with Primitive Secretory Phenotype and Smooth Muscle-rich Stroma,” Acta Neuropathologica, Vol. 111, No. 4, 2006, pp. 397-399. doi:10.1007/s00401-006-0065-9
[36]	N. Sakashita, M. Yamada, T. Nakagawa, H. Yamasaki and M. Takeya, “A Leiomyomatoid Angiomatous Neuroendocrine tumor of the Myometrium: Case Study with Ultrastructural Analysis,” Human Pathology, Vol. 39, No. 5, 2008, pp. 788-792. doi:10.1016/j.humpath.2007.09.017
[37]	R. Avritscher, R. B. Iyer1, J. Ro and G. Whitman, “LipoleioMyoma of the Uterus,” American Journal of Radiology, Vol. 177, 2001, p. 856.